Fibrocytes: potential new therapeutic targets for pulmonary hypertension?

Stenmark K.R., Frid M.G., Yeager M.E.

Source: Eur Respir J 2010; 36: 1232-1235

Journal Issue: December

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Stenmark K.R., Frid M.G., Yeager M.E.. Fibrocytes: potential new therapeutic targets for pulmonary hypertension?. Eur Respir J 2010; 36: 1232-1235

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2014; 44: 842-845 Year: 2014
Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications Source: Eur Respir J 2010; 35: 418-425 Year: 2010
Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003
Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021
Pulmonary hypertension in ILDs: novel therapeutic data Source: International Congress 2019 – Lungs in the fog Year: 2019
Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010
Lung transplantation for pulmonary hypertension: the impact of new drug therapies Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria? Year: 2004
“New potential diagnostic biomarkers for pulmonary hypertension.” Source: Eur Respir J 2016; 48: 962 Year: 2016
Chronic post-embolic pulmonary hypertension: a new target for medical therapies?}, Source: Eur Respir Rev 2013; 22: 258-264 Year: 2013
New potential diagnostic biomarkers for pulmonary hypertension Source: Eur Respir J 2015; 46: 1390-1396 Year: 2015
What do we learn from novel genes in pulmonary hypertension? Source: Virtual Congress 2020 – Don't blame your parents: causes of pulmonary hypertension in early life Year: 2020
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019
Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Source: Eur Respir J 2006 Oct 01;28(4):683-686 Year: 2006
Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
LSC 2010 Abstract: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases Year: 2010
Gene therapeutic approaches: from stem cell therapy to gene delivery Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006
Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016